Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy
Makaleler > Tam Makale · 2016
Yazarlar: Carlos Aguiar, Eduardo Alegria, Ricardo C. Bonnadonna, Alberico L. Catapano, Francesco Consentido, Moses Elisaf, Michel Farnier, Jean Fierrieres, Pasquale Perronre Filardi, Nicolae Hancu, Latife Meral KAYIKÇIOĞLU, Alberto Mello E Silva, Jesus Millan, Zeljko Reiner, Lale Tokgozoglu, Paul Valensi, Margas Viigimaa, Michal Vrablik, Alberto Zambon, Jose Luis Zamorano, Roberto Ferrari, Mariano Blasco, Angel Brea, Angel Diaz, Pedro Gonzales Santos, Antonio Hernandez Mijares, Teresa Mantilla, Juan Pedro-Botet, Xavier Pinto
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, AHCI İndekslerine Giren Dergi, Uluslararası, 2016, cilt 28, ss 87-93
DOI: 10.1016/j.arteri.2015.12.001
Özet
LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk.